Field MedicalAnnounce its coreFieldForceAwarded FDA "Breakthrough Device" Designation, the product is intended for treating persistent monomorphic scar-related ventricular tachycardia (VT)."The FDA's recognition of this breakthrough technology highlights the urgent need for treating complex, life-threatening ventricular tachycardia."Field Medical's ablation system has the potential to redefine ventricular arrhythmia care for both doctors and patients.”---Vivek Reddy Mount Sinai Health System"The FDA's TAP Pilot Acceptance and Breakthrough Device Designation for the FieldForce Ablation System are key milestones in our regulatory approval process. This recognition advances our vision of providing electrophysiologists with the next generation of focused PFA tools to enable rapid and convenient ventricular tachycardia care."---Steven Mickelsen CEO of Field MedicalAtrial fibrillation occurs in only half of the patients with arrhythmia, while other types of arrhythmia include others.Atrial Tachycardia (Non-AF),Ventricular TachycardiaTachycardia, etc. Among themVentricular TachycardiaTachycardia is a very fatal type of arrhythmia. According to guideline estimatesUltraMore than 7 million people suffer from clinical ventricular arrhythmias such as ventricular tachycardia and frequent ventricular premature beats.Ventricular TachycardiaTachycardia is one of the most unmet clinical needs in electrophysiological disorders. Current treatmentThe Best Treatment for Ventricular Tachycardia---Implant HeartImplantable Cardioverter Defibrillator (ICD), butImplant HeartThe therapeutic effect of the implantable cardioverter defibrillator (ICD) is not satisfactory, completelyCannot prevent disease progression or cure the disease, and ICD therapy is expensive and the treatment process is painful.
Traditional thermal ablation technology can only be used as a second-line treatment option, the reasonThe ventricular wall is much thicker than the atrial wall.Ventricular tachycardia ablation often requires ablating a larger and deeper ablation area.Traditional Thermal Ablation TechnologyUnable to achieve the required ablation depth, even with thermal ablation treatment, in half of the patients.Patients will experience recurrence within 6 months after ablation. It can be said that traditional thermal ablation is very unreliable.
For this reason, both domestic and international electrophysiology companies want to use PFA technology for treatment.Ventricular TachycardiaTachycardia.Field MedicalIs a leading company in this field, with its core productFieldForceClinical research was initiated at the beginning of the year. In additionField MedicalIn addition, Medtronic's Sphere-9 ablation catheter is also conducting clinical research in the United States, belonging to the same tier as Field Medical.
However, compared with Sphere-9,FieldForceSpecifically forVentricular TachycardiaDesigned for rapidity. Initially designed with consideration of the ventricular physiological structure, thusFieldForceHas special advantages in the treatment of ventricular tachycardia.
FieldForceYesField MedicalThe core products, including catheters and energy generators.FieldForceOvercoming the limitations of the first-generation PFA technology and addressing the significant unmet need for treating any arrhythmia, while expanding the capability to treat complex ventricular arrhythmias.In order to make PFA curableVentricular Tachycardia,Field MedicalDeveloping a New TechnologyFieldBending, andFieldBendingTechnology forFieldForce。FieldBendingA technique that predictably concentrates energy around the catheter and reduces unwanted far-field effects, thereby enhancing efficacy and safety. Ultimately,FieldBendingThe ultra-targeted energy allows for more accurate and concentrated application of power to the target tissue, enabling deeper penetration of energy into the tissue and achieving a wider range of ablation.
Field MedicalIt is an innovative company focused on the field of pulsed field catheter ablation. Founded by Dr. Steven Mickelsen in 2022, it is developing a patented technology called FieldBending, which aims to concentrate therapeutic effects and reduce the harmful far-field effects associated with first-generation PFA technology.Field MedicalAiming to expand the indications of pulsed field ablation (PFA) beyond atrial fibrillation treatment by addressing more challenging ventricular arrhythmias and common procedures such as supraventricular tachycardia (SVT) that require minimal sedation.
